Table 1. First-line antiretroviral therapy strategies, regimen components and market shares.

STR Strategy	gMTR Strategy	% Patients Initiating
EFV/TDF/FTC	gEFV+TDF+g3TC	30.4%a [14]
RPV/TDF/FTC	RPV+TDF+g3TC	26.1%a [14]
EVG/COBI/TDF/FTC	EVG/COBI+TDF+g3TC	43.5%a [14]

COBI, cobicistat; EFV, efavirenz; EVG, elvitegravir; FTC, emtricitabine; g3TC, generic lamivudine; gEFV, generic efavirenz; gMTR, generic multiple-tablet regimen; RPV, rilpivirine; STR, single-tablet regimen; TDF, tenofovir.

^aPercentage of patients initiating corresponding ART regimen.